Email this article Immunoliposomes as a promising antiviral agent against SARS-COV-2
- Authors: Bobik T.V.1, Simonova M.A.1, Rushkevich N.U.1, Kostin N.N.1, Skryabin G.A.1, Knorre V.D.1, Schulga A.A.1, Konovalova E.V.1, Proshkina G.M.1, Gabibov A.G.1,2, Deev S.M.1,3
-
Affiliations:
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
- M.V. Lomonosov Moscow State University
- National Research University Higher School of Economics
- Issue: Vol 514, No 1 (2024)
- Pages: 50-55
- Section: Articles
- URL: https://journals.rcsi.science/2686-7389/article/view/258937
- DOI: https://doi.org/10.31857/S2686738924010099
- EDN: https://elibrary.ru/I KRWHSS
- ID: 258937
Cite item
Open Access
Access granted
Abstract
According to the World Health Organization, as of September 13, 2023, there have been approximately 23 million confirmed cases of COVID-19 reported in the Russian Federation, about 400 thousand of which were fatal. Considering the high rate of mutation of the RNA-containing virus genome, which inevitably leads to the emergence of new infectious strains (Eris and Pyrola), the search for medicinal antiviral agents remains an urgent task. Moreover, taking into account the actively mutating receptor-binding domain, this task requires fundamentally new solutions.
This study proposes a candidate immunoliposomal drug that targets the S protein of SARS-CoV-2 by the monoclonal neutralizing antibody P4A1 and ensures the penetration of a highly active ribonuclease into the virus-infected cell, which degrades, among cellular RNA, viral RNA too. We demonstrate a more than 40-fold increase in the neutralizing activity of the developed drug compared to the free monoclonal neutralizing antibody.
Keywords
Full Text
About the authors
T. V. Bobik
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Author for correspondence.
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
M. A. Simonova
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
N. U. Rushkevich
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
N. N. Kostin
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
G. A. Skryabin
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
V. D. Knorre
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
A. A. Schulga
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
E. V. Konovalova
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
G. M. Proshkina
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences
Email: bobik_tanya@mail.ru
Russian Federation, Moscow
A. G. Gabibov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; M.V. Lomonosov Moscow State University
Email: bobik_tanya@mail.ru
Academician of the RAS
Russian Federation, Moscow; MoscowS. M. Deev
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences; National Research University Higher School of Economics
Email: bobik_tanya@mail.ru
Academician of the RAS
Russian Federation, Moscow; MoscowReferences
- WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int
- Widyasari K., Kim J. A review of the currently available antibody therapy for the treatment of coronavirus disease 2019 (COVID-19) // Antibodies. 2023. V. 12. № 1. Р. 5.
- Lu L., Ding Y., Zhang Y., et al. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII // Int. J. Nanomedicine. 2018. V. 13. P. 1927–1944.
- Di J., Xie F., Xu Y. When liposomes met antibodies: Drug delivery and beyond // Adv. Drug Deliv. 2020. V. 154–155. P. 151–162.
- Park J. W., Kirpotin D. B., Hong K., et al. Tumor targeting using anti-her2 immunoliposomes // Journal of Controlled Release. 2001. V. 74. P. 95–113.
- Ott S., Wunderli-Allenspach H. Liposomes and influenza viruses as an in vitro model for membrane interactions I. Kinetics of membrane fusion and lipid transfer // Eur J Pharm Sci. 1994. V. 1. № 6. Р. 323–332.
- Guo Y., Huang L., Zhang G., et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes // Nat. Commun. 2021. V. 12. № 1. Р. 2623.
- Deyev S., Proshkina G., Baryshnikova O., et al. Selective staining and eradication of cancer cells by protein-carrying DARP in-functionalized liposomes // Eur. J. Pharm. Biopharm. 2018. V. 130. P. 296–305.
- Kruglova N., Siniavin A., Gushchin Vol., et al. Different neutralization sensitivity of SARS-CoV-2 cell-to-cell and cell-free modes of infection to convalescent sera // Viruses. 2021. V. 13. P. 1133.
- Kostin N. N., Bobik T. V., Skryabin G. A., et al. An ELISA platform for the quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies as an alternative to monitoring of the virus-neutralizing activity // Acta Nat. 2022. V. 14. P. 109–119.
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays // J Immunol Methods. 1983. V. 65 (1–2). P. 55–63.
- Jost C., Schilling J., Tamaskovic R. et al. A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2 // Structure. 2013. V. 21. P. 1979–1991.
- Zhang Z., King M. R. Neutralization of the new coronavirus by extracting their spikes using engineered liposomes // Nanomedicine. 2023. V. 50. P. 102674.
Supplementary files
